[68Ga-PSMA-11 PET/mpMRI for local detection of primary prostate cancer in men with a negative prior biopsy].

Autor:	Maurer T; Urologische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München.; Martini-Klinik und Klinik und Poliklinik für Urologie, Universität Hamburg-Eppendorf., Gesterkamp H; Urologische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München., Nguyen N; Urologische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München., Westenfelder K; Urologische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München., Gschwend JE; Urologische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München., Budäus L; Martini-Klinik und Klinik und Poliklinik für Urologie, Universität Hamburg-Eppendorf., Rauscher I; Nuklearmedizinische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München., Vag T; Nuklearmedizinische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München., Weber W; Nuklearmedizinische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München., Eiber M; Nuklearmedizinische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München.
Jazyk:	němčina
Zdroj:	Aktuelle Urologie [Aktuelle Urol] 2021 Apr; Vol. 52 (2), pp. 143-148. Date of Electronic Publication: 2020 Aug 27.
DOI:	10.1055/a-1198-2305
Abstrakt:	Introduction and Objective: Multiparametric MRI (mpMRI) represents the current gold standard for the detection of primary prostate cancer (PC) after a negative biopsy. PSMA PET imaging has been introduced in the diagnostic work-up of PC with high accuracy, but is currently mainly utilised in the setting of biochemical recurrence. This study aimed to determine the efficacy of combined ⁶⁸ Ga-PSMA-11 PET/mpMRI imaging to detect PC in patients with previously negative prostate biopsies. Methods: A total of 57 patients who had undergone at least one prior negative prostate biopsy were included in this retrospective analysis. All patients underwent ⁶⁸ Ga-PSMA-11 PET/mpMRI imaging of the prostate. mpMRI was evaluated according to the PIRADS classification system and ⁶⁸ Ga-PSMA-11 PET was rated on a 5-point Likert scale (1: PC highly unlikely; 2: PC unlikely; 3: presence of PC is equivocal; 4: PC likely; 5: PC highly likely). All patients received a systematic random biopsy as well as a targeted transrectal biopsy of lesions suspicious on imaging. Imaging and histological biopsy outcomes were compared on a per-patient basis. Results: In the histological analysis, 35/57 (61.4 %) patients harboured PC lesions. In patients with biopsy-proven PC, 21/35 (60.0 %) had a PI-RADS 4 or 5 lesion on mpMRI and 28 /35 (80.0 %) had a PET rating of 4 or 5. Combined ⁶⁸ Ga-PSMA-11 PET/mpMRI missed only one patient with a Gleason score (GS) 7a tumour (rating of 1 or 2 in both PET and mpMRI). Limitations include the retrospective analysis as well as possible false negative biopsy results even in a fusion biopsy setting. Conclusion: In this initial analysis, the combined ⁶⁸ Ga-PSMA-11 PET/mpMRI proved to be a valuable imaging tool to guide prostate biopsies for the detection of PC in patients with a negative prior biopsy. In this approach, ⁶⁸ Ga-PSMA-11 PET and mpMRI show partially complementary findings that enhance the detection of PC lesions. Competing Interests: Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht. (Thieme. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu